Landscapes / Targets
CD8
6 drugs act on CD8, in 7 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs6
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
AstraZeneca · Public AZN |
Phase 1/2 | 29 Mar 2029Phase 1/2 trial completes | ||
| Next date | 29 Mar 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Prostate Cancer | ||||
| Open drug page | |||||
— |
AstraZeneca · Public AZN |
Phase 1/2 | 2 Oct 2029Phase 1/2 trial completes | ||
| Next date | 2 Oct 2029 · Phase 1/2 trial completes | ||||
| Also tested for | Melanoma, Non-small Cell Lung Cancer and 7 more | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Dec 2026Phase 1 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | HNSCC, Melanoma and 4 more | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Mar 2027Phase 1 trial completes | |||
| Next date | 31 Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | Type 1 Diabetes | ||||
| Open drug page | |||||
In vivo CD19 CAR-T, mRNA in CD8-targeted lipid nanoparticles |
Phase 1 | 31 May 2027Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 31 May 2027 · Phase 1 trial completes | ||||
| Also tested for | Systemic Lupus Erythematosus, Scleroderma and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Solid Tumor, Non Small Cell Lung Cancer and 3 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 6 of 6 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026